|
|
|
|
LEADER |
01000naa a22002652 4500 |
001 |
NLM313475237 |
003 |
DE-627 |
005 |
20231225150643.0 |
007 |
cr uuu---uuuuu |
008 |
231225s2020 xx |||||o 00| ||eng c |
024 |
7 |
|
|a 10.2144/btn-2020-0088
|2 doi
|
028 |
5 |
2 |
|a pubmed24n1044.xml
|
035 |
|
|
|a (DE-627)NLM313475237
|
035 |
|
|
|a (NLM)32772558
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a eng
|
100 |
1 |
|
|a Toma, Ryan
|e verfasserin
|4 aut
|
245 |
1 |
2 |
|a A clinically validated human capillary blood transcriptome test for global systems biology studies
|
264 |
|
1 |
|c 2020
|
336 |
|
|
|a Text
|b txt
|2 rdacontent
|
337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
500 |
|
|
|a Date Completed 09.08.2021
|
500 |
|
|
|a Date Revised 09.08.2021
|
500 |
|
|
|a published: Print-Electronic
|
500 |
|
|
|a Citation Status MEDLINE
|
520 |
|
|
|a To prevent and treat chronic diseases, including cancer, a global application of systems biology is needed. We report here a whole blood transcriptome test that needs only 50 μl of capillary (fingerprick) blood. This test is suitable for global applications because the samples are preserved at ambient temperature for up to 4 weeks and the RNA preservative inactivates all pathogens, enabling safe transportation. Both the laboratory and bioinformatic steps are automated and performed in a clinical lab, which minimizes batch effects and creates unbiased datasets. Given its clinical testing performance and accessibility to traditionally underrepresented and diverse populations, this test offers a unique ability to reveal molecular mechanisms of disease and enable longitudinal, population-scale studies
|
650 |
|
4 |
|a Journal Article
|
650 |
|
4 |
|a RNA-seq
|
650 |
|
4 |
|a clinically validated
|
650 |
|
4 |
|a population studies
|
650 |
|
4 |
|a systems biology
|
650 |
|
4 |
|a transcriptomics
|
650 |
|
4 |
|a whole blood
|
700 |
1 |
|
|a Duval, Nathan
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Pelle, Benjamin
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Parks, Matthew M
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Gopu, Vishakh
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Torres, Pedro J
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Camacho, Francine R
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Shen, Nan
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Krishnan, Subha
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Hatch, Andrew
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Tily, Hal
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Perlina, Ally
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Banavar, Guruduth
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Vuyisich, Momchilo
|e verfasserin
|4 aut
|
773 |
0 |
8 |
|i Enthalten in
|t BioTechniques
|d 1988
|g 69(2020), 4 vom: 01. Okt., Seite 289-301
|w (DE-627)NLM012627046
|x 1940-9818
|7 nnns
|
773 |
1 |
8 |
|g volume:69
|g year:2020
|g number:4
|g day:01
|g month:10
|g pages:289-301
|
856 |
4 |
0 |
|u http://dx.doi.org/10.2144/btn-2020-0088
|3 Volltext
|
912 |
|
|
|a GBV_USEFLAG_A
|
912 |
|
|
|a SYSFLAG_A
|
912 |
|
|
|a GBV_NLM
|
912 |
|
|
|a GBV_ILN_21
|
912 |
|
|
|a GBV_ILN_22
|
912 |
|
|
|a GBV_ILN_39
|
912 |
|
|
|a GBV_ILN_40
|
912 |
|
|
|a GBV_ILN_50
|
912 |
|
|
|a GBV_ILN_60
|
912 |
|
|
|a GBV_ILN_62
|
912 |
|
|
|a GBV_ILN_65
|
912 |
|
|
|a GBV_ILN_70
|
912 |
|
|
|a GBV_ILN_99
|
912 |
|
|
|a GBV_ILN_121
|
912 |
|
|
|a GBV_ILN_130
|
912 |
|
|
|a GBV_ILN_227
|
912 |
|
|
|a GBV_ILN_350
|
912 |
|
|
|a GBV_ILN_618
|
912 |
|
|
|a GBV_ILN_640
|
912 |
|
|
|a GBV_ILN_754
|
912 |
|
|
|a GBV_ILN_2001
|
912 |
|
|
|a GBV_ILN_2002
|
912 |
|
|
|a GBV_ILN_2003
|
912 |
|
|
|a GBV_ILN_2005
|
912 |
|
|
|a GBV_ILN_2006
|
912 |
|
|
|a GBV_ILN_2007
|
912 |
|
|
|a GBV_ILN_2008
|
912 |
|
|
|a GBV_ILN_2009
|
912 |
|
|
|a GBV_ILN_2010
|
912 |
|
|
|a GBV_ILN_2012
|
912 |
|
|
|a GBV_ILN_2015
|
912 |
|
|
|a GBV_ILN_2018
|
912 |
|
|
|a GBV_ILN_2023
|
912 |
|
|
|a GBV_ILN_2035
|
912 |
|
|
|a GBV_ILN_2040
|
912 |
|
|
|a GBV_ILN_2060
|
912 |
|
|
|a GBV_ILN_2099
|
912 |
|
|
|a GBV_ILN_2105
|
912 |
|
|
|a GBV_ILN_2121
|
912 |
|
|
|a GBV_ILN_2470
|
951 |
|
|
|a AR
|
952 |
|
|
|d 69
|j 2020
|e 4
|b 01
|c 10
|h 289-301
|